Background: Hepatitis C virus (HCV)is a health issue that affects a significant proportion of the global
population. HCV infection is a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma. The new
generation of oral direct-acting antivirals (DDAs) has transformed the treatment of hepatitis C virus infection,
demonstrating both high efficacy and high tolerability, it is extremely effective and safe. Aim: This study aimed to assess
quality of life among hepatitis C virus patients undergoing Direct Acting Antivirals. Method: Descriptive research design
was utilized, included 150 HCV patients undergoing DDAs at Specialty Medical Hospital, Mansoura International
Hospital and Bilqas Central Hospital. Data was collected by using two tools, structured interviewing questionnaire and
the Chronic -Liver -Disease -Questionnaire. Results: fatigue was the most affected quality of life domain among our
study subjects, the majority of our subject reported presence of fatigue all of the time. Activity was the followed quality
of life domain affected. Bodily pain was the most affected symptoms in systemic symptom domain. Having problems
with concentration was the most affected symptoms in emotional function domain. Abdominal symptoms and worry
were the least affected quality of life domains among our subjects. Recommendations: Fatigue and activity were the
highly problems that faced our study subject so, assessment and management for fatigue and activity should be done for
those patients. Bodily pain was the most affected symptom related to systemic symptoms domains among our subjects
so, assessment and management of these symptoms are very essential. Further researches should be done on larger and
randomized selected sample to generalize the results. Developing fatigue intervention program for this population is
highly recommended. Pain relieving measure program should be done for this population.